Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan vs Docetaxel in Advanced NSCLC
NCT05089734Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of sacituzumab govitecan in non-small cell lung cancer (NSCLC), sponsored by Gilead Sciences. Started Nov 2021; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05089734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089734.